17731 Evolving resolution of clinical, cellular, and transcriptomic inflammatory markers during 1-year IL-17A inhibition by secukinumab

Introduction: The objective was to determine the effect of 52-week secukinumab treatment on clinical and transcriptomic psoriasis markers. Materials and methods Biopsies of lesional and non-lesional skin from 24 patients receiving secukinumab 300 mg subcutaneously over 52 weeks (NCT01537432) were used for immunohistochemistry and gene expression analysis. The composition of the residual-disease genomic profile (RDGP; ie, molecular scar) after successful treatment with secukinumab was determined at week 12 and week 52.